Single high-dose MRI-guided radiation for prostate cancer in lymph nodes
Tests one high-dose MRI-guided radiation treatment in men with prostate cancer returning in lymph nodes.
Plain-language title generated from the registry record
Registry title: MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
Key facts
- Where
- Odense, DenmarkSee the site
Where in Denmark
- Department of Oncology, Odense University HospitalOdense, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Odense University Hospital
- Trial code
- NCT07635108
- Record updated
- 15 June 2026
- Original description
This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative treatment. Participants receive one fraction of 24 Gy delivered with MR-guided stereotactic body radiotherapy (SBRT), which uses MRI to visualise the tumour and surrounding organs during treatment. The main goal is to assess safety (severe side effects). The trial also evaluates local tumour control, longer-term side effects, time until hormone (androgen deprivation) therapy is needed, survival, and quality of life. The trial aims to enrol 48 patients.Read full original descriptionShow less
Improved MR-Guided Single-fraction Stereotactic Sblative Radiotherapy in Pelvic and Abdominal Nodal Oliorecurrent Prostate Cancer
This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative treatment. Participants receive one fraction of 24 Gy delivered with MR-guided stereotactic body radiotherapy (SBRT), which uses MRI to visualise the tumour and surrounding organs during treatment. The main goal is to assess safety (severe side effects). The trial also evaluates local tumour control, longer-term side effects, time until hormone (androgen deprivation) therapy is needed, survival, and quality of life. The trial aims to enrol 48 patients.
Inclusion: Age ≥ 18 years; Signed informed consent; Histologically proven initial diagnosis of adenocarcinoma of the prostate; ECOG performance status 0-2; Biochemical recurrence after curatively intended local treatment (radical prostatectomy and/or radiotherapy), with PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen; Any additional sites of disease beyond the protocol-specified target lymph nodes must be considered suitable for ablative treatment; Life expectancy > 6 months; Lymph node size ≤ 2 cm.
Exclusion: Overlap between prior radiation fields and the current target area leading to high risk of clinically significant normal-tissue injury; Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease); Uncontrolled intercurrent illness; Medical contraindications to MRI; Inability to tolerate the physical set-up required for SABR.